VolitionRx (VNRX)
Builds blood-based diagnostics from nucleosome measurement and chromatin enrichment.
Something off on this page? Send us feedback.
Develops blood-based diagnostic technologies based on nucleosome measurement and chromatin enrichment, selling veterinary tests, research-use kits, and laboratory services while developing human-health assays. Revenue combines products and services with a partner-led licensing model that relies on clinical validation, regulatory clearance, reimbursement, analyzer integration, and distribution.
Develops blood-based diagnostic technologies that measure circulating nucleosomes or enrich tumor-associated chromatin for liquid-biopsy analysis. Its Nu.Q platform spans commercially available canine cancer screening, a CE-marked Nu.Q NETs assay, and research-use Nu.Q Discover kits and laboratory services. Nu.Q Cancer and Capture-PCR/Capture-Seq remain development programs.
Generates product and service revenue and pursues licenses, milestones, and royalties, while keeping research and development, key assay components, and intellectual property in-house. Research and production are centered in Belgium, but commercialization runs through diagnostics partners, reference laboratories, analyzer platforms, and regional distributors across several markets.
Clinical validation, jurisdiction-specific authorization, reimbursement, installed-platform integration, and partner execution determine the timing and reach of its diagnostic products.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $2.8M · Total debt $12.0M · Total assets $8.3M · Shareholders' equity −$32.2M
- Revenue
- $398.7K
- Operating income
- −$4.2M
- Net income
- −$7.3M
No dividends on record.
| Institutions | 16.03% | 1.93M shares | |
|---|---|---|---|
| 26 holders · as of Jun 30, 2026 | |||
| Other | 83.97% | 10.11M shares | |
| remainder | |||
12.04M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Lagoda Investment Management, L.P.Institution | 12.09% | 1.46M | as of Jun 30, 2026 |
Luminus Management LLCInstitution | 1.30% | 156,897 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.46% | 55,537 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 0.42% | 50,684 | as of Jun 30, 2026 |
Wealthspire Advisors, LLCInstitution | 0.37% | 45,000 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Abbott
Cancer screening and MRD monitoring scale through Exact Sciences.
- Guardant Health
Blood-based screening, profiling, and monitoring across cancer care.
- GRAIL
Multi-cancer blood screening targets the same early-detection pathway.
- Caris Life Sciences
Multi-cancer blood testing and molecular profiling compete for oncology use.
- Natera
ctDNA MRD testing contests cancer recurrence and treatment monitoring.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| VolitionRx | $0.2555 | −3.55% | $2.2M | — | — | 0.9 | −0.3% |
| Abbott | $104.04 | +1.03% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| Guardant Health | $177.50 | +2.09% | $23.33B | — | — | 19.7 | +44.3% |
| GRAIL | $109.77 | +1.67% | $4.63B | — | — | 28.0 | +25.7% |
| Caris Life Sciences | $32.17 | +4.97% | $8.66B | 85.6 | 127.8 | 8.8 | +45.4% |
| Natera | $387.24 | +4.48% | $53.08B | — | — | 19.6 | +37.7% |
| Median | 59.4 | 72.9 | 19.6 | +37.7% |